Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New feature: Introducing the Finviz Matrix

Adlai Nortye Ltd.

Contributing Author

Recent Articles by Adlai Nortye Ltd.

Aug-14	Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress ANL GlobeNewswire
Aug-03	Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia ANL GlobeNewswire
Jul-16	Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 ANL +6.77% GlobeNewswire
Jul-13	Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists ANL -6.38% GlobeNewswire
Apr-16	Adlai Nortye Announces $150.0 Million Private Placement Equity Financing ANL GlobeNewswire
Feb-12	Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations ANL GlobeNewswire
Feb-03	Adlai Nortye Announces $140.0 Million Private Placement Equity Financing ANL GlobeNewswire
Dec-29	Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China ANL +9.76% GlobeNewswire
Nov-21	Adlai Nortye to Participate in Upcoming Investor Conferences ANL -5.59% GlobeNewswire
Oct-22	Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ANL GlobeNewswire
Oct-13	Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ANL +5.15% GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)